To include your compound in the COVID-19 Resource Center, submit it here.

Tracon reports Phase Ib data for carotuximab in NSCLC

In October, Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported data from 8 evaluable patients with stage IV non-squamous non-small cell lung cancer (NSCLC) in

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE